27975209|t|Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia
27975209|a|Post-bariatric hypoglycaemia (PBH) is a rare, but severe, metabolic disorder arising months to years after bariatric surgery. It is characterised by symptomatic postprandial hypoglycaemia, with inappropriately elevated insulin concentrations. The relative contribution of exaggerated incretin hormone signalling to dysregulated insulin secretion and symptomatic hypoglycaemia is a subject of ongoing inquiry. This study was designed to test the hypothesis that PBH and associated symptoms are primarily mediated by glucagon-like peptide-1 (GLP-1). We conducted a double-blinded crossover study wherein eight participants with confirmed PBH were assigned in random order to intravenous infusion of the GLP-1 receptor (GLP-1r) antagonist. Exendin (9-39) (Ex-9), or placebo during an OGTT on two separate days at the Stanford University Clinical and Translational Research Unit. Metabolic, symptomatic and pharmacokinetic variables were evaluated. Results were compared with a cohort of BMI - and glucose -matched non-surgical controls (NSCs). Infusion of Ex-9 decreased the time to peak glucose and rate of glucose decline during OGTT, and raised the postprandial nadir by over 70%, normalising it relative to NSCs and preventing hypoglycaemia in all PBH participants. Insulin AUC and secretion rate decreased by 57% and 71% respectively, and peak postprandial insulin was normalised relative to NSCs. Autonomic and neuroglycopenic symptoms were significantly reduced during Ex-9 infusion. GLP-1r blockade prevented hypoglycaemia in 100% of individuals, normalised beta cell function and reversed neuroglycopenic symptoms, supporting the conclusion that GLP-1 plays a primary role in mediating hyperinsulinaemic hypoglycaemia in PBH. Competitive antagonism at the GLP-1r merits consideration as a therapeutic strategy. ClinicalTrials.gov NCT02550145.
27975209	18	23	GLP-1	T103	UMLS:C0061355
27975209	39	67	post-bariatric hypoglycaemia	T038	UMLS:C0020615
27975209	68	96	Post-bariatric hypoglycaemia	T038	UMLS:C0020615
27975209	98	101	PBH	T038	UMLS:C0020615
27975209	126	144	metabolic disorder	T038	UMLS:C0025517
27975209	175	192	bariatric surgery	T058	UMLS:C1456587
27975209	242	255	hypoglycaemia	T038	UMLS:C0020615
27975209	287	294	insulin	T103	UMLS:C0021641
27975209	352	368	incretin hormone	T103	UMLS:C1562292
27975209	369	379	signalling	T038	UMLS:C3537152
27975209	396	413	insulin secretion	T038	UMLS:C1256369
27975209	430	443	hypoglycaemia	T038	UMLS:C0020615
27975209	482	487	study	T062	UMLS:C2603343
27975209	529	532	PBH	T038	UMLS:C0020615
27975209	548	556	symptoms	T033	UMLS:C1457887
27975209	583	606	glucagon-like peptide-1	T103	UMLS:C0061355
27975209	608	613	GLP-1	T103	UMLS:C0061355
27975209	631	645	double-blinded	T062	UMLS:C0013072
27975209	646	661	crossover study	T062	UMLS:C0150097
27975209	676	688	participants	T098	UMLS:C0679646
27975209	704	707	PBH	T038	UMLS:C0020615
27975209	741	761	intravenous infusion	T058	UMLS:C0021440
27975209	769	783	GLP-1 receptor	T103	UMLS:C0378073
27975209	785	791	GLP-1r	T103	UMLS:C0378073
27975209	793	803	antagonist	T103	UMLS:C0003139
27975209	805	819	Exendin (9-39)	T103	UMLS:C0247947
27975209	821	825	Ex-9	T103	UMLS:C0247947
27975209	831	838	placebo	T058	UMLS:C0032042
27975209	849	853	OGTT	T058	UMLS:C0029161
27975209	882	901	Stanford University	T092	UMLS:C0041740
27975209	902	942	Clinical and Translational Research Unit	T092	UMLS:C1274109
27975209	1042	1048	cohort	T098	UMLS:C0599755
27975209	1052	1055	BMI	T201	UMLS:C1305855
27975209	1062	1069	glucose	T103	UMLS:C0017725
27975209	1109	1117	Infusion	T058	UMLS:C0574032
27975209	1121	1125	Ex-9	T103	UMLS:C0247947
27975209	1153	1160	glucose	T103	UMLS:C0017725
27975209	1173	1180	glucose	T103	UMLS:C0017725
27975209	1196	1200	OGTT	T058	UMLS:C0029161
27975209	1296	1309	hypoglycaemia	T038	UMLS:C0020615
27975209	1317	1320	PBH	T038	UMLS:C0020615
27975209	1321	1333	participants	T098	UMLS:C0679646
27975209	1335	1342	Insulin	T103	UMLS:C0021641
27975209	1351	1360	secretion	T038	UMLS:C0312431
27975209	1427	1434	insulin	T103	UMLS:C0021641
27975209	1468	1477	Autonomic	T033	UMLS:C2674101
27975209	1482	1506	neuroglycopenic symptoms	T033	UMLS:C1457887
27975209	1541	1545	Ex-9	T103	UMLS:C0247947
27975209	1546	1554	infusion	T058	UMLS:C0574032
27975209	1556	1562	GLP-1r	T103	UMLS:C0378073
27975209	1582	1595	hypoglycaemia	T038	UMLS:C0020615
27975209	1607	1618	individuals	T098	UMLS:C0237401
27975209	1631	1649	beta cell function	T038	UMLS:C0007613
27975209	1654	1687	reversed neuroglycopenic symptoms	T033	UMLS:C1457887
27975209	1720	1725	GLP-1	T103	UMLS:C0061355
27975209	1760	1791	hyperinsulinaemic hypoglycaemia	T038	UMLS:C1864903
27975209	1795	1798	PBH	T038	UMLS:C0020615
27975209	1812	1822	antagonism	T038	UMLS:C0013159
27975209	1830	1836	GLP-1r	T103	UMLS:C0378073